TPS

Transcranial Pulse Stimulation (TPS^®) continues to be on the road to success: The 100th NEUROLITH^® system was installed at the beginning of June 2022. The latest TPS^® location is the Lengg Clinic in Zurich, Switzerland. Dr. med. Bartosz Bujan (Medical Director Neurorehabilitation) is one of the pioneers of TPS^® in Switzerland and now offers the therapy option for patients with Alzheimer's dementia. To celebrate this important milestone and look to the future, a small celebration was held on June 16 at STORZ MEDICAL's headquarters.

»New hope for Alzheimer's patients: Patient's memory improves«*: On 22 April 2022, the front-page lead story of Germany's highest-circulation daily newspaper BILD (reach 7.62 million predominantly older readers) was about Transcranial Pulse Stimulation (TPS^®) with the NEUROLITH^®.

It's getting exciting: In the RTL News report »Neue Alzheimer-Therapie: Sanfte Stosswellen bringen Gedächtnis zurück«. Prof. Dr Musa Citak introduces in his practice in Hamburg the NEUROLITH^® system and the treatment method, Transcranial Pulse Stimulation – short TPS^®.
TPS^® as a modern therapy method for the treatment of Alzheimer's dementia stimulates different brain regions even in deeper areas.

In early January 2022, a study on the development of global dementia prevalence published by the medical journal The Lancet Public Health¹ received a lot of attention. The study predicts that the number of cases will triple to 152.8 million by 2050.The World Alzheimer Report 2019 already came to a similar assessment. The most important factors for this explosive development are the ageing of the global population and its further growth.

Transcranial Pulse Stimulation (TPS^®) celebrates its debut in Ukraine: The first NEUROLITH^® system was installed in the western Ukrainian city and cultural centre of Lviv (approx. 750,000 inhabitants) on 12 January 2022. Now, Alzheimer's patients can receive treatment at »BRAINSPOT LVIV«, a clinic for neuromodulation (Director: Tomas Dzeminskyy, Chief Medical Officer: Andrii Hul). The first therapy sessions have already taken place.

A study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in January 2022 investigates the long-term effects of Transcranial Pulse Stimulation (TPS^®) with the NEUROLITH^® system on human brain and behaviour.¹ The randomised, sham-controlled and double-blinded study provides sham-controlled evidence for such effects for the first time.

Another study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in February 2022 now presented a detailed sub-analysis of possible anti-depressive effects of Transcranial Pulse Stimulation (TPS^®) with the NEUROLITH^® system based on neuropsychological and functional imaging data.²

Anfang Januar 2022 wurde in der medizinischen Fachzeitschrift The Lancet Public Health¹ eine vielbeachtete Studie zur Entwicklung der weltweiten Demenz-Prävalenz publiziert. Diese sagt bis zum Jahr 2050 eine Verdreifachung der Fallzahlen auf 152,8 Millionen voraus. Zu einer ähnlichen Einschätzung kam bereits der World Alzheimer Report 2019. Die wichtigsten Faktoren für diese explosive Entwicklung sind die Alterung der weltweiten Bevölkerung sowie deren weiteres Wachstum.

In diesem hochinformativen Webinar sprechen unsere Key Speaker über wissenschaftliche Hintergründe und klinische Daten der Transkraniellen Pulsstimulation (TPS^®) bei Patienten mit Alzheimer-Demenz und teilen Praxiserfahrungen mit der Handhabung und den klinischen Auswirkungen. Anschliessend geht es in eine offene Diskussion mit einer Q&A Session über. Gerne können Sie uns Fragen rund um das Thema NEUROLITH^® & TPS^® auch bereits im Vorfeld senden.

Eine im Januar 2022 publizierte Studie von Matt et al. (Medizinische Universität Wien, Universitätsklinik für Neurologie) untersucht die Langzeiteffekte der Transkraniellen Pulsstimulation (TPS^®) mit dem NEUROLITH^®-System auf das menschliche Gehirn und Verhalten.¹ Die randomisierte, placebokontrollierte und doppelt verblindete Studie liefert erstmals einen scheinkontrollierten Nachweis für entsprechende Effekte.

In this information-packed webinar, neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation (TPS^®) in patients with Alzheimer’s Dementia as well as practical experience with handling and clinical effects.

Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS^®) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH^® system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH^® in the capital of Bavaria, the largest German state.

Transcranial Pulse Stimulation (TPS^®) with the NEUROLITH^® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey.

In early May 2021, two more NEUROLITH^® systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS^®).

There are various forms of brain stimulation, that are used in neurodegenerative disease. In this webinar neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation as well as practical experience with handling and clinical effects. Which patient to choose? How does TPS^® compare to TMS?

The live webinar »Transcranial Pulse Stimulation (TPS^®) in Patients with Alzheimer`s Disease« with Prof. Dr Roland Beisteiner will be hosted by SOTERIX Medical in cooperation with STORZ MEDICAL.

Transcranial Pulse Stimulation (TPS^®) is a revolutionary new technique that delivers ultrasound-based pulse stimulation using shock waves.

Transcranial Pulse Stimulation (TPS^®) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH^® system was successfully installed in the Praxis Alexander Russ in Zurich.

In December 2018, STORZ MEDICAL has received the CE approval for the NEUROLITH^®, a new therapy system for the treatment of neurological diseases.

Throughout the world, more and more specialised medical centres are using Transcranial Pulse Stimulation (TPS^®) with the NEUROLITH^® system for the treatment of patients with Alzheimer’s disease. In June 2020, another NEUROLITH^® system was installed successfully at the private hospital »Rudolfinerhaus Privatklinik« in Vienna, Austria, where it will be used under the medical direction of Dr Matthias Geisler. On-site training of the hospital’s treatment team was carried out by Dr Henning Lohse-Busch (Rheintalklinik, Bad Krozingen, Germany) who also played a decisive role in the development of TPS^®.

In 2019 the NEUROLITH^® shock wave system was successfully introduced to the market. The Transcranial Pulse Stimulation (TPS^®) device, which was developed by STORZ MEDICAL in Switzerland, is the only medical device marketed in Europe that is approved in the European Union for the treatment of the central nervous system of patients with Alzheimer's disease. The effect of TPS^® is now being investigated in another neurological condition: In September 2020, the world's first clinical study for the treatment of Parkinson's patients with shock wave therapy using real-time documentation started at MedUni Vienna (Department of Neurology) in Austria under the direction of Professor Roland Beisteiner.

In December 2019, the first study¹ on Transcranial Pulse Stimulation (TPS^®) with STORZ MEDICAL’s NEUROLITH^® system was published in the prestigious journal Advanced Science. In the study, Beisteiner et al. evaluate the TPS^® method and present treatment results. The presented data shows that it is possible to improve brain performance with TPS^® and that there is a long-term effect.